MétaCan
Menu
Back to cohort
Record W4414857553 · doi:10.1093/oncolo/oyaf327

Pathomic immune biomarkers define recurrence risk in early-stage melanoma

2025· article· en· W4414857553 on OpenAlexaff
Thazin Nwe Aung, Ajay Singh, Gerardo Espinoza, Chenxin Zhang, Tianyun Jiang, Divya Kenchappa, Yadriel Bracero, Swanand Rakhade, Sharmin Sultana, Suryansh Shukla, Emily Nghiem, Matteo Abbruzzese, Chaoyuan Kuang, Larisa J. Geskin, David Entenberg, Robyn D. Gartrell, Tammie Ferringer, Lawrence W. Leung, Jee‐Young Moon, Basil A. Horst, Kent L. Nastiuk, David L. Rimm, Rui Chang, Yvonne M. Saenger

Bibliographic record

VenueThe Oncologist · 2025
Typearticle
Languageen
FieldMedicine
TopicCutaneous Melanoma Detection and Management
Canadian institutionsUniversity of British ColumbiaColumbia College
FundersNational Cancer InstituteNational Institutes of Health
KeywordsMelanomaImmune systemDiseaseStage (stratigraphy)Prospective cohort studyBiomarker

Abstract

fetched live from OpenAlex

BACKGROUND: There is an urgent need for biomarkers in early-stage melanoma because the benefit of adjuvant immunotherapy is marginal while the toxicity is considerable. Immune surveillance is a key mechanism limiting melanoma progression, but no immune biomarkers have yet been sufficiently validated for clinical use. METHODS: We validate 3 digital pathology biomarkers, all previously trained in published cohorts and testable in formalin fixed paraffin embedded specimens, for correlation with recurrence free survival and distant metastatic free survival: (1) tumor infiltrating lymphocytes identified using artificial intelligence in digital images (eTILs), (2) nanoString melanoma immune profile (MIP), and (3) quantitative immunofluorescence of CD8+ cells. RESULTS: Three immune biomarkers were validated and found to correlate with recurrence at 36 months by receiver operating curve analysis (eTILs area under the curve [AUC] = 0.706, P = .002; MIP AUC = 0.775, P < .001; and CD8% AUC = 0.682, P = .009) and define high and low risk groups using Kaplan Meier (KM) curves within the IIA-IIID population (P = .007 for eTILs and P < .001 for MIP and CD8%) and within the difficult to treat IIB-IIIA subset (P = .005, P < .001, P < .001, respectively). Immune biomarkers enhance clinical predictors (P = .012, P < .001, P = .004), and correlate with distant metastatic recurrence (P = .031, P = .047, P = .014, respectively). Network analysis shows that stage and depth combined with pathomic immune features yields the highest correlation with recurrence (AUC = 0.875, P < .001). CONCLUSIONS: Immune biomarkers should be prospectively validated in stage II-III melanoma for the purpose of avoiding overtreatment of low-risk patients and to stratify high-risk patients for clinical trials.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.521
Threshold uncertainty score0.364

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.016
GPT teacher head0.285
Teacher spread0.269 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueThe OncologistSame topicCutaneous Melanoma Detection and ManagementFrench-language works237,207